Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
According to NICE guidance, healthcare professionals should provide clear safety-netting advice when prescribing GLP-1 receptor agonists, including information about expected side effects and warning signs requiring medical review
[1] Dose-escalation studies, such as a 12-week trial on gradual titration, revealed that beginning at lower doses (e.g., 4 mg) and slowly increasing to therapeutic levels significantly reduced the incidence of nausea, vomiting, and diarrhoea
SCFAs promotes intestinal barrier integrity, pancreatic -cell proliferation and insulin biosynthesis, where enteric dysbiosis reduces SCFAs synthesis (Tan et al., 2014
The LEADER, SUSTAIN-6, and REWIND trials collectively demonstrate the cardiovascular outcome benefits of GLP-1 receptor agonists in people with type 2 diabetes and at high CVD risk
US$ 22.15
US$ 23.45
US$ 25.17
